{
    "clinical_study": {
        "@rank": "166502", 
        "arm_group": {
            "arm_group_label": "LY2940680", 
            "arm_group_type": "Experimental", 
            "description": "Oral LY2940680 will be administered at escalating doses (100 mg up to 400 mg) once daily in 28-day cycles. Treatment with LY2940680 may continue until disease progression, unacceptable toxicity, or other discontinuation criteria are met."
        }, 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to assess the safety and tolerability of LY2940680 up\n      to the global recommended dose in Japanese participants with advanced solid cancers."
        }, 
        "brief_title": "A Study of LY2940680 in Japanese Participants With Advanced Cancers", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasm Metastasis", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have histological or cytological evidence of a diagnosis of solid tumor that is\n             advanced and/or metastatic.  The participant must be, in the judgment of the\n             investigator, an appropriate candidate for the experimental therapy after available\n             standard therapies have failed to provide clinical benefit for their disease\n\n          -  Have the presence of measurable or nonmeasurable disease as defined by the Response\n             Evaluation Criteria in Solid Tumors Guideline Version 1.1\n\n          -  Have adequate organ function\n\n          -  Have discontinued all previous therapies for cancer, including chemotherapy,\n             radiotherapy, cancer-related hormonal therapy for at least 3 weeks (6 weeks for\n             mitomycin-C or nitrosoureas, 2 weeks for palliative radiation therapy for bone\n             metastasis) prior to study enrollment, and have recovered from the acute effects of\n             any such therapy\n\n          -  Males must agree to use medically approved barrier contraceptive precautions during\n             the study and for 6 months following the last dose of study drug\n\n          -  Females with child bearing potential must agree to use medically approved\n             contraceptive precautions during the study and for 6 months following the last dose\n             of study drug; have had a negative serum pregnancy test \u22647 days before the first dose\n             of study drug\n\n          -  A breastfeeding woman must not be breastfeeding. If a female who stops breastfeeding\n             enters the study, the female must stop breastfeeding from the day of the first study\n             drug administration until at least 6 months after the last administration\n\n          -  Have an estimated life expectancy, in the judgment of the investigator, which will\n             permit the participant to complete 2 cycles of treatment\n\n          -  Are able to swallow tablets\n\n        Exclusion Criteria:\n\n          -  Have received treatment within 21 days of the study enrollment with any agent that\n             has not received regulatory approval for any indication\n\n          -  Have symptomatic central nervous system (CNS) malignancy or metastasis.  Participants\n             with treated brain metastases are eligible if they are clinically stable with regard\n             to neurologic function and off steroids after cranial irradiation ending at least 14\n             days prior to enrollment, or after surgical resection performed at least 28 days\n             prior to enrollment\n\n          -  Have known current hematologic malignancies or acute or chronic leukemia\n\n          -  Have a known active fungal, bacterial, and/or known viral infection including human\n             immunodeficiency (HIV) or viral (A, B, or C) hepatitis, potentially affecting the\n             conduct of this study\n\n          -  Have a second primary malignancy that in the judgment of the investigator and sponsor\n             may affect the interpretation of results\n\n          -  Have QTc interval of >470 milliseconds (msec) on screening electrocardiogram (ECG)\n\n          -  Have serious preexisting medical conditions or serious concomitant systemic disorders\n             that, in the opinion of the investigator, would preclude participation in this study\n\n          -  Have received any medication that is a strong inhibitor of cytochrome P4503A4\n             (CYP3A4) within 7 days prior to receiving study drug"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919398", 
            "org_study_id": "14895", 
            "secondary_id": "I4J-MC-HHBH"
        }, 
        "intervention": {
            "arm_group_label": "LY2940680", 
            "description": "Administered orally", 
            "intervention_name": "LY2940680", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Shizuoka", 
                        "country": "Japan", 
                        "zip": "411-8777"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "104-0045"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT-5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with LY2940680 Dose-Limiting Toxicities (DLT)", 
            "safety_issue": "Yes", 
            "time_frame": "Cycle 1 (28 Days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919398"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2640680 and a Major Metabolite of LY2940680 (LSN3185556)", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1: Predose through 24 hours post dose on Days 1 and 15. Cycle 2: Predose through 2 hours post dose on Days 1 and predose on Day 15. Cycle 3 - 4: Predose on Days 1 and 15"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Concentration time (AUC) of LY2640680 and a Major Metabolite of LSN3185556", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1: Predose through 24 hours post dose on Days 1 and 15. Cycle 2: Predose through 2 hours post dose on Days 1 and predose on Day 15. Cycle 3 - 4: Predose on Days 1 and 15"
            }, 
            {
                "measure": "Percentage of Participants with a Tumor Response", 
                "safety_issue": "No", 
                "time_frame": "Baseline to study completion (estimated as 4 months)"
            }, 
            {
                "measure": "Pharmacodynamic (PD): Gene Expression Level of Hedgehog (Hh) Regulated Genes (Including Gli1) in Skin", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 2 hours post dose on Day 15 in Cycle 1, Predose on Day 1 in Cycle 2"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}